{"id":744897,"date":"2014-11-17T11:45:00","date_gmt":"2014-11-17T11:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/"},"modified":"2023-03-22T00:04:48","modified_gmt":"2023-03-22T04:04:48","slug":"vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/","title":{"rendered":"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the investigational IMPROVE-IT study met its<br \/>\n      primary and all secondary composite efficacy endpoints. In IMPROVE-IT,<br \/>\n      patients taking the LDL-cholesterol-lowering medicine VYTORIN<sup>\u00ae <\/sup>(ezetimibe\/simvastatin)<br \/>\n      \u2013 which combines simvastatin with the non-statin ZETIA<sup>\u00ae<\/sup><br \/>\n      (ezetimibe) &#8212; experienced significantly fewer major cardiovascular<br \/>\n      events (as measured by a composite of cardiovascular death, non-fatal<br \/>\n      myocardial infarction, non-fatal stroke, re-hospitalization for unstable<br \/>\n      angina or coronary revascularization occurring at least 30 days after<br \/>\n      randomization) than patients treated with simvastatin alone. The results<br \/>\n      from this 18,144-patient study of high-risk patients presenting with<br \/>\n      acute coronary syndromes were presented today during the late-breaking<br \/>\n      clinical trials session at the American Heart Association 2014<br \/>\n      Scientific Sessions.\n    <\/p>\n<p>\n      Because high-risk patients treated with statins, including those on<br \/>\n      treatment with low levels of LDL-cholesterol (LDL-C), continue to be at<br \/>\n      increased cardiovascular risk, IMPROVE-IT was designed to address<br \/>\n      whether lowering LDL-C to well under 70 mg\/dL by adding ezetimibe to a<br \/>\n      statin further reduced cardiovascular events. In IMPROVE-IT, at seven<br \/>\n      years, 32.7 percent of patients taking VYTORIN experienced a primary<br \/>\n      endpoint event compared to 34.7 percent of patients taking simvastatin<br \/>\n      alone (hazard ratio of 0.936, p=0.016). Based on the LDL-C range<br \/>\n      compared in the study\u2019s treatment arms (at one year, a mean LDL-C of 53<br \/>\n      mg\/dL versus 70 mg\/dL, respectively), the 6.4 percent relative risk<br \/>\n      reduction observed in the VYTORIN arm in IMPROVE-IT was consistent with<br \/>\n      the treatment effect that had been projected based on prior studies of<br \/>\n      statins.\n    <\/p>\n<p>\n      Merck plans to submit the data from IMPROVE-IT to the U.S. Food and Drug<br \/>\n      Administration in mid-2015 to support a new indication for reduction of<br \/>\n      major cardiovascular events for VYTORIN and ZETIA. VYTORIN and ZETIA are<br \/>\n      currently indicated for use along with a healthy diet to reduce elevated<br \/>\n      LDL cholesterol in patients with hyperlipidemia. The current U.S.<br \/>\n      Prescribing Information for both products states that the effect of<br \/>\n      ezetimibe on cardiovascular morbidity and mortality, alone or<br \/>\n      incremental to statin therapy, has not been determined.\n    <\/p>\n<p>\n      \u201cIn IMPROVE-IT, the addition of ezetimibe to a statin resulted in a<br \/>\n      further reduction in cardiovascular events compared to statin therapy<br \/>\n      alone, which is the first time this has been directly shown in a study<br \/>\n      of a non-statin cholesterol-lowering medicine,\u201d said study co-chairs,<br \/>\n      Drs. Eugene Braunwald of Harvard Medical School and Robert Califf of<br \/>\n      Duke University. \u201cThe IMPROVE-IT data also address an important<br \/>\n      scientific question about lowering LDL-C to very low levels.\u201d\n    <\/p>\n<p>\n      VYTORIN (ezetimibe\/simvastatin) should not be taken with strong CYP3A4<br \/>\n      inhibitors (e.g., itraconazole, ketoconazole, posaconazole,<br \/>\n      voriconazole, HIV protease inhibitors, boceprevir, telaprevir,<br \/>\n      erythromycin, clarithromycin, telithromycin, nefazodone, and<br \/>\n      cobicistat-containing products); or with gemfibrozil, cyclosporine, or<br \/>\n      danazol. VYTORIN also should not be taken by anyone with active liver<br \/>\n      disease, unexplained persistent elevations of hepatic transaminase<br \/>\n      levels, or hypersensitivity to the product; or by women who are<br \/>\n      pregnant, nursing or may become pregnant. ZETIA (ezetimibe) should not<br \/>\n      be taken by people with hypersensitivity to any component of the<br \/>\n      medication. Statin contraindications also apply when ZETIA is used with<br \/>\n      these drugs: statins are contraindicated in patients with active liver<br \/>\n      disease, unexplained persistent elevations in hepatic transaminase<br \/>\n      levels and in pregnant and nursing women. Refer to individual statin<br \/>\n      labels for details about who should not take that statin.\n    <\/p>\n<p>\n      <b>IMPROVE-IT compared very low LDL-C levels &#8212; a range at or below 70<br \/>\n      mg\/dL<\/b>\n    <\/p>\n<p>\n      In IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy<br \/>\n      International Trial), the LDL-C levels compared were very low. At one<br \/>\n      year, the mean LDL-C level was 53 mg\/dL in the VYTORIN group and 70<br \/>\n      mg\/dL in the simvastatin group, with a between-group difference of 17<br \/>\n      mg\/dL. When the IMPROVE-IT study was initiated in 2005, the optional<br \/>\n      recommended target LDL-C level in the United States for acute coronary<br \/>\n      syndrome patients and other groups considered to be at very high risk<br \/>\n      for cardiovascular events was <70 mg\/dL. Prior cardiovascular outcomes \n      studies of statins have not compared treatments at such low LDL-C levels \n      (see Table).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignc\">\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"11\">\n          \u00a0\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\" colspan=\"11\">\n          <b>Table: LDL-C Comparison Ranges Between Treatment Arms in Selected<br \/>\n          Trials*<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>Trial<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>IDEAL<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(2005)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>TNT<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(2005)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>PROVE-IT<\/b><br \/><b>(2004)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>A to Z<\/b><br \/><b>(2004)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          <b>IMPROVE-IT<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(2014)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>LDL-C<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>Comparison Range<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>(mg\/dL)<\/b><sup><b>\u00a7<\/b><\/sup>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          104<br \/><i>vs.<\/i><br \/>81\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          101<br \/><i>vs.<\/i><br \/>77\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          95<br \/><i>vs.<\/i><br \/>62\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          77<br \/><i>vs.<\/i><br \/>63\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n          70<br \/><i>vs.<\/i><br \/>53\n        <\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"11\">\n          *Blazing, et al. Am H J 2014; 168: 205-212.<\/p>\n<p class=\"bwcellpmargin\">\n            <sup>\u00a7<\/sup>All values are expressed as means except PROVE-IT and<br \/>\n            A to Z, which are expressed as medians.\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          \u00a0\n        <\/td>\n<\/tr>\n<tr>\n<td>\n          \u00a0\n        <\/td>\n<td colspan=\"11\">\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/table>\n<p>\n      At the start of the study, the average baseline LDL-C was approximately<br \/>\n      95 mg\/dL. Among treatment-na\u00efve patients (about two-thirds of those in<br \/>\n      the study), the mean baseline LDL-C was 101 mg\/dL. Among patients on<br \/>\n      prior lipid lowering therapy at enrollment, the mean baseline LDL-C was<br \/>\n      80 mg\/dL.\n    <\/p>\n<p>\n      <b>Additional efficacy and safety results from IMPROVE-IT<\/b>\n    <\/p>\n<p>\n      Patients in IMPROVE-IT were initially randomized to treatment with<br \/>\n      VYTORIN (ezetimibe\/simvastatin) 10\/40 mg or simvastatin 40 mg. Patients<br \/>\n      were followed for up to nine years, with a median clinical follow-up of<br \/>\n      approximately six years. In this event-driven study, 5,314 primary<br \/>\n      endpoint events were reported.\n    <\/p>\n<p>\n      In addition to the significant result on the primary composite efficacy<br \/>\n      endpoint, patients taking VYTORIN experienced significant reductions<br \/>\n      compared to patients taking simvastatin alone on the three secondary<br \/>\n      composite efficacy endpoints, as follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        VYTORIN reduced the incidence of the composite endpoint of death due<br \/>\n        to all causes, major coronary events, and non-fatal stroke; this<br \/>\n        endpoint occurred in 38.7 percent of patients taking VYTORIN and 40.3<br \/>\n        percent of patients taking simvastatin only (hazard ratio of 0.948,<br \/>\n        p=0.034).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        VYTORIN reduced the incidence of the composite endpoint of death due<br \/>\n        to coronary heart disease (CHD), non-fatal myocardial infarction (MI),<br \/>\n        and urgent coronary revascularization with either percutaneous<br \/>\n        coronary intervention (PCI) or coronary artery bypass graft (CABG)<br \/>\n        occurring at least 30 days after randomization; this endpoint occurred<br \/>\n        in 17.5 percent of patients taking VYTORIN and 18.9 percent of<br \/>\n        patients taking simvastatin only (hazard ratio of 0.912, p=0.016).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        VYTORIN reduced the incidence of the composite endpoint of<br \/>\n        cardiovascular death, non-fatal MI, documented unstable angina that<br \/>\n        requires admission into a hospital, all revascularization (including<br \/>\n        both coronary and non-coronary) occurring at least 30 days after<br \/>\n        randomization, and non-fatal stroke; this endpoint occurred in 34.5<br \/>\n        percent of patients taking VYTORIN and 36.2 percent of patients taking<br \/>\n        simvastatin only (hazard ratio of 0.945, p=0.035).\n      <\/li>\n<\/ul>\n<p>\n      There were no significant differences between treatment groups in<br \/>\n      adverse events of special interest, which included myopathy and<br \/>\n      rhabdomyolysis, gallbladder adverse events, liver enzyme elevations<br \/>\n      greater than or equal to three times the upper limit of normal (ULN) and<br \/>\n      cancer. These safety findings from IMPROVE-IT were generally consistent<br \/>\n      with current labeling for ezetimibe. Among 9,067 patients in the<br \/>\n      ezetimibe\/simvastatin group vs. 9,077 patients in the simvastatin group,<br \/>\n      myopathy was reported in 0.2 percent vs. 0.1 percent of patients,<br \/>\n      respectively; rhabdomyolysis was reported in 0.1 percent vs. 0.2<br \/>\n      percent; gallbladder-related adverse events were reported in 3.1 percent<br \/>\n      vs. 3.5 percent; cholecystectomy was reported in 1.5 percent vs. 1.5<br \/>\n      percent; and alanine aminotransferase (ALT) and\/or aspartate<br \/>\n      transaminase (AST) elevations (greater than or equal to three times ULN,<br \/>\n      consecutive) were reported in 2.5 percent vs. 2.3 percent of patients.<br \/>\n      Over seven years, cancer was reported in 10.2 percent of patients in<br \/>\n      both treatment groups.\n    <\/p>\n<p>\n      \u201cWe believe that the IMPROVE-IT study makes an important scientific<br \/>\n      contribution to the body of evidence relating LDL-cholesterol levels to<br \/>\n      cardiovascular risk,\u201d said Dr. Roger Perlmutter, president, Merck<br \/>\n      Research Laboratories. \u201cWe are grateful to our collaborators at Harvard<br \/>\n      and Duke who led the study, their fellow investigators, and to the<br \/>\n      thousands of patients around the world who participated in this study<br \/>\n      for their efforts.\u201d\n    <\/p>\n<p>\n      <b>About VYTORIN<\/b><sup><b>\u00ae<\/b><\/sup><b> (ezetimibe\/simvastatin)<\/b>\n    <\/p>\n<p>\n      VYTORIN contains ezetimibe and simvastatin. VYTORIN is indicated as<br \/>\n      adjunctive therapy to diet for the reduction of total cholesterol, LDL<br \/>\n      cholesterol, apolipoprotein B, triglycerides, and non\u2013HDL cholesterol,<br \/>\n      and to increase HDL cholesterol in patients with primary (heterozygous<br \/>\n      familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia when<br \/>\n      diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for VYTORIN states that no incremental<br \/>\n      benefit of VYTORIN on cardiovascular morbidity and mortality over and<br \/>\n      above that demonstrated for simvastatin has been established. VYTORIN is<br \/>\n      not indicated to reduce cardiovascular events in patients who have<br \/>\n      presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about VYTORIN<\/b>\n    <\/p>\n<p>\n      All patients starting therapy with VYTORIN, or whose dose of VYTORIN is<br \/>\n      being increased, should be advised of the risk of myopathy, including<br \/>\n      rhabdomyolysis, and told to promptly report any unexplained muscle pain,<br \/>\n      tenderness, or weakness particularly if accompanied by malaise or fever<br \/>\n      or if muscle signs and symptoms persist after discontinuing VYTORIN.<br \/>\n      VYTORIN should be discontinued immediately if markedly elevated creatine<br \/>\n      kinase (CK) levels occur or myopathy is diagnosed or suspected. VYTORIN<br \/>\n      contains simvastatin, which occasionally causes myopathy manifested as<br \/>\n      muscle pain, tenderness, or weakness with CK levels above 10 times ULN.<br \/>\n      Myopathy sometimes takes the form of rhabdomyolysis with or without<br \/>\n      acute renal failure secondary to myoglobinuria, and rare fatalities have<br \/>\n      occurred. Predisposing factors for myopathy include advanced age (\u226565<br \/>\n      years), female gender, uncontrolled hypothyroidism, and renal<br \/>\n      impairment. The risk of myopathy, including rhabdomyolysis, is dose<br \/>\n      related.\n    <\/p>\n<p>\n      The 10\/80 mg dose of VYTORIN should not be started in new patients. The<br \/>\n      risk of myopathy, including rhabdomyolysis, is greater in patients<br \/>\n      taking simvastatin 80 mg compared with other statin therapies with<br \/>\n      similar or greater LDL cholesterol lowering efficacy, and with lower<br \/>\n      doses of simvastatin. The 10\/80 mg dose of VYTORIN<br \/>\n      (ezetimibe\/simvastatin) should be used only in patients who have been<br \/>\n      taking that dose chronically (e.g., for 12 months or more) without<br \/>\n      evidence of muscle toxicity. If a patient who is currently tolerating<br \/>\n      the 10\/80 mg dose needs to be initiated on an interacting drug that is<br \/>\n      contraindicated or is associated with a dose cap for simvastatin, that<br \/>\n      patient should be switched to an alternative statin or statin-based<br \/>\n      regimen with less potential for the drug-drug interaction. Please read<br \/>\n      Warnings and Precautions in the Prescribing Information for additional<br \/>\n      information.\n    <\/p>\n<p>\n      In addition to<b> <\/b>drugs that are contraindicated<b> <\/b>because of<br \/>\n      an increased risk of myopathy\/rhabdomyolysis, grapefruit juice should be<br \/>\n      avoided. Use caution when prescribing VYTORIN with a fenofibrate, and<br \/>\n      immediately discontinue both drugs if myopathy is diagnosed or<br \/>\n      suspected. Cases of myopathy, including rhabdomyolysis, have been<br \/>\n      reported with simvastatin coadministered with colchicine, and caution<br \/>\n      should be used when prescribing VYTORIN with colchicine.\n    <\/p>\n<p>\n      The dose of VYTORIN should not exceed 10\/10 mg daily in patients<br \/>\n      receiving verapamil, diltiazem or dronedarone, and 10\/20 mg daily in<br \/>\n      patients receiving amiodarone, amlodipine or ranolazine. For patients<br \/>\n      with homozygous familial hypercholesterolemia (HoFH) taking lomitapide,<br \/>\n      the dose should not exceed 10\/20 mg\/day (or 10\/40 mg\/day for patients<br \/>\n      who have previously taken simvastatin 80 mg\/day chronically, e.g., for<br \/>\n      12 months or more, without evidence of muscle toxicity); patients<br \/>\n      initiating lomitapide should have their dose of VYTORIN reduced by 50%.<br \/>\n      The benefits of combined use of VYTORIN with these drugs, other<br \/>\n      fenofibrates, or niacin (\u22651 g\/day) should be carefully weighed against<br \/>\n      the potential risk of myopathy\/rhabdomyolysis. Caution should be used<br \/>\n      when Chinese patients taking niacin (\u22651 g\/day) are coadministered doses<br \/>\n      of VYTORIN exceeding 10\/20 mg\/day; Chinese patients should not receive<br \/>\n      VYTORIN 10\/80 mg with niacin.\n    <\/p>\n<p>\n      Persistent elevations in hepatic transaminase can occur. Liver function<br \/>\n      tests should be performed at treatment initiation and thereafter when<br \/>\n      clinically indicated. If serious liver injury with clinical symptoms<br \/>\n      and\/or hyperbilirubinemia or jaundice occurs during treatment, therapy<br \/>\n      should be interrupted promptly and not restarted unless an alternate<br \/>\n      etiology is found.\n    <\/p>\n<p>\n      Increases in HbA1c and fasting serum glucose levels have been reported<br \/>\n      with statins, including simvastatin.\n    <\/p>\n<p>\n      In clinical trials, the most commonly reported side effects, regardless<br \/>\n      of cause, included headache (5.8 percent), increased ALT (3.7 percent),<br \/>\n      myalgia (3.6 percent), upper respiratory tract infection (3.6 percent),<br \/>\n      and diarrhea (2.8 percent).\n    <\/p>\n<p>\n      VYTORIN tablets contain ezetimibe and simvastatin: 10 mg of ezetimibe<br \/>\n      and 10, 20, 40, or 80 mg of simvastatin (VYTORIN 10\/10, 10\/20, 10\/40, or<br \/>\n      10\/80 mg, respectively). The usual dosage range is 10\/10 mg\/day to 10\/40<br \/>\n      mg\/day; patients should not be titrated to the restricted 10\/80-mg dose.\n    <\/p>\n<p>\n      <b>About ZETIA (ezetimibe)<\/b>\n    <\/p>\n<p>\n      ZETIA, administered alone or in combination with a statin, is indicated<br \/>\n      as adjunctive therapy to diet for the reduction of elevated total<br \/>\n      cholesterol, LDL cholesterol, apolipoprotein B, and non-HDL cholesterol<br \/>\n      in patients with primary (heterozygous familial and non-familial)<br \/>\n      hyperlipidemia when diet alone is not enough.\n    <\/p>\n<p>\n      The Prescribing Information for ZETIA states that the effect of ZETIA on<br \/>\n      cardiovascular morbidity and mortality has not been determined. ZETIA is<br \/>\n      not indicated for use with a statin to further reduce cardiovascular<br \/>\n      events in patients who have presented with acute coronary syndromes.\n    <\/p>\n<p>\n      <b>Selected cautionary information about ZETIA<\/b>\n    <\/p>\n<p>\n      When using ZETIA with a statin, also follow the label recommendations<br \/>\n      for that specific statin.\n    <\/p>\n<p>\n      When ZETIA was coadministered with a statin, consecutive elevations in<br \/>\n      hepatic transaminase levels (greater than or equal to 3 times ULN) were<br \/>\n      slightly higher (1.3 percent) than those of statins alone (0.4 percent).<br \/>\n      Liver function tests should be performed when ZETIA is added to statin<br \/>\n      therapy and according to statin recommendations. Should an increase in<br \/>\n      ALT or AST greater than or equal to 3 times ULN persist, consider<br \/>\n      withdrawal of ZETIA and\/or the statin.\n    <\/p>\n<p>\n      Patients should be advised to promptly report muscle pain, tenderness,<br \/>\n      or weakness. Risk for skeletal muscle toxicity increases with higher<br \/>\n      statin doses, advanced age (>65), hypothyroidism, renal impairment, and<br \/>\n      depending on the statin used, concomitant use of other drugs.<br \/>\n      Discontinue drug if myopathy is diagnosed or suspected.\n    <\/p>\n<p>\n      ZETIA is not recommended in patients with moderate to severe hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      The coadministration of ZETIA with fibrates other than fenofibrate is<br \/>\n      not recommended until use in patients is adequately studied. Exercise<br \/>\n      caution when using ZETIA and cyclosporine concomitantly because exposure<br \/>\n      to both drugs is increased. Cyclosporine concentrations should be<br \/>\n      monitored in these patients.\n    <\/p>\n<p>\n      ZETIA should be used in pregnant or nursing women only if the benefit<br \/>\n      outweighs the risk.\n    <\/p>\n<p>\n      In clinical trials, regardless of causality assessment, the most<br \/>\n      frequent side effects for ZETIA coadministered with a statin versus a<br \/>\n      statin alone included nasopharyngitis (3.7 percent vs 3.3 percent),<br \/>\n      myalgia (3.2 percent vs 2.7 percent), upper respiratory tract infection<br \/>\n      (2.9 percent vs 2.8 percent), arthralgia (2.6 percent vs 2.4 percent),<br \/>\n      and diarrhea (2.5 percent vs 2.2 percent); for ZETIA administered alone<br \/>\n      vs placebo: upper respiratory tract infection (4.3 percent vs 2.5<br \/>\n      percent), diarrhea (4.1 percent vs 3.7 percent), arthralgia (3.0 percent<br \/>\n      vs 2.2 percent), sinusitis (2.8 percent vs 2.2 percent), pain in<br \/>\n      extremity (2.7 percent vs 2.5 percent), and fatigue (2.4 percent vs 1.5<br \/>\n      percent).\n    <\/p>\n<p>\n      <b>Additional information about the IMPROVE-IT study<\/b>\n    <\/p>\n<p>\n      IMPROVE-IT was an international, multi-center, randomized, double-blind<br \/>\n      active comparator trial of 18,144 high-risk patients presenting with<br \/>\n      acute coronary syndromes (ACS), including unstable angina (UA),<br \/>\n      non-ST-segment elevation acute myocardial infarction (NSTEMI), and<br \/>\n      ST-segment elevation acute myocardial infarction (STEMI). The study<br \/>\n      assessed the incidence of major cardiovascular events, as measured by a<br \/>\n      composite of cardiovascular death, non-fatal MI, non-fatal stroke,<br \/>\n      re-hospitalization for ACS, or coronary revascularization (occurring 30<br \/>\n      days or more after the initial event), in patients treated with<br \/>\n      ezetimibe\/simvastatin (VYTORIN) compared with patients treated with<br \/>\n      simvastatin alone.\n    <\/p>\n<p>\n      All patients in the trial were started at doses of ezetimibe\/simvastatin<br \/>\n      10\/40 mg or simvastatin 40 mg. Prior to a 2011 protocol amendment, the<br \/>\n      dose could be titrated to ezetimibe\/simvastatin 10\/80 mg or simvastatin<br \/>\n      80 mg if successive LDL-C values exceeded 79 mg\/dL. The study enrolled<br \/>\n      patients within 10 days of ACS hospitalization who had sufficient risk<br \/>\n      as defined in the protocol and who had an initial LDL-C of \u2264125 mg\/dL if<br \/>\n      lipid-lowering drug na\u00efve or <100 mg\/dL if on a prior prescription \n      lipid-lowering therapy identified as no more potent than simvastatin 40 \n      mg\/day. The LDL-C entry limitations were designed to enroll patients \n      reasonably anticipated to achieve LDL-C levels of 70 mg\/dL or less in \n      the simvastatin only cohort, which was the optional recommended target \n      set in the 2004 update to the Adult Treatment Panel (ATP) III guidelines.\n    <\/p>\n<p>\n      For additional information about the study, please see the accompanying <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fnews%2FIMPROVE-IT_Backgrounder_Timeline.pdf&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=study+timeline&#038;index=1&#038;md5=bb82b1b33f07b8e0a9e9b7775ddcd93b\" rel=\"nofollow\">study<br \/>\n      timeline<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=b6a26e9640bed6336c6614c356d1109e\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=1465bf29d2bcf8a28a5da0b152d13ac9\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=506826f022cbbfb9046e9c795f51e676\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=00d28068b89d0977f78bb0fed457474e\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=30abc3e73214741b5a8c9038dad320d7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for VYTORIN<br \/>\n      (ezetimibe\/simvastatin) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_pi.pdf&#038;index=7&#038;md5=777f714f253873b6b2cb416b610fbc4d\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for VYTORIN at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvytorin%2Fvytorin_ppi.pdf&#038;index=8&#038;md5=27e01a2d0caff9d2bcc8bcd9d0ce6304\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/vytorin\/vytorin_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZETIA (ezetimibe) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_pi.pdf&#038;index=9&#038;md5=50d7d973075cec1bb5a2485f277c67ef\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for ZETIA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&#038;esheet=50985011&#038;newsitemid=20141117005291&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzetia%2Fzetia_ppi.pdf&#038;index=10&#038;md5=68cacb59546fef9aaca841e382f8d5bf\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zetia\/zetia_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20141117005291r1&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contact:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Investor        Contact:<br \/>Joe Romanelli, 908-423-5185     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) &#8211; experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Because high-risk patients treated with statins, including those on<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-744897","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Because high-risk patients treated with statins, including those on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/\",\"name\":\"VYTORIN\u00ae (ezetimibe\\\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-11-17T11:45:00+00:00\",\"dateModified\":\"2023-03-22T04:04:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VYTORIN\u00ae (ezetimibe\\\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/","og_locale":"en_US","og_type":"article","og_title":"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN \u00ae (ezetimibe\/simvastatin) \u2013 which combines simvastatin with the non-statin ZETIA \u00ae (ezetimibe) - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Because high-risk patients treated with statins, including those on","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:48+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/","name":"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-11-17T11:45:00+00:00","dateModified":"2023-03-22T04:04:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20141117005291r1&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/vytorin-ezetimibe-simvastatin-significantly-reduced-cardiovascular-events-more-than-simvastatin-alone-in-patients-presenting-with-acute-coronary-syndromes-in-the-investigational-improve-it-stu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"VYTORIN\u00ae (ezetimibe\/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"212d9abe-42f9-4434-a32e-5738ab1d6a39","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744897\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744897"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}